ACTRIMS 2024
Multiple Sclerosis News Today is providing coverage of the ninth annual Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2024 Feb. 29-March 2 in West Palm Beach, Florida. The theme of this year’s conference is “Breaking Barriers in MS.”
People with relapsing forms of multiple sclerosis (MS) being treated with an infusion CD20 inhibitor such as Ocrevus (ocrelizumab) can safely transition to the more recent Briumvi (ublituximab-xiiy), which is given in shorter infusion times. That’s according to data from the ENHANCE Phase 3b clinical trial…
Recommended Posts
- ACTRIMS 2026: Scientists, at ‘crossroads,’ look at MS research
- ACTRIMS 2024: Switch to Briumvi well tolerated in relapsing MS
- ACTRIMS 2024: MRI Paramagnetic rim lesions tied to cognitive decline
- ACTRIMS 2024: An antihistamine may speed MS disease progression
- ACTRIMS 2024: 2 treatments to aid remyelination near clinical trials